23rd March 2024

Confidant Classes

for LAW | CLAT | JUDICIARY

Home | Edu NEWS | Dexamethasone

Dexamethasone

The use of , which is used to reduce inflammation in other diseases such as arthritis, has been approved for patients who require oxygen and those who have an excessive inflammatory response.

  • The government on Saturday authorized the use of dexamethasone, a low-cost steroid, as an alternative to methylprednisolone to treat patients with moderate and severe symptoms.
  • Union Department of Health has published a revised version of the “Clinical Management Protocol: COVID-19”, a document published for the use of health professionals as a reference. Earlier this month, the ministry added loss of smell and taste as new symptoms of COVID-19 in the manual.
  • The World Health Organization has called for a rapid increase in the production of dexamethasone after British clinical trials have found that it can save lives in critically ill coronavirus patients.
  • Dexamethasone, a low-dose steroid, has been on the market for more than 60 years and is generally used to reduce inflammation.
  • Recently, researchers led by a team from the University of Oxford administered dexamethasone to more than 2,000 critically ill patients hospitalized with the new coronavirus. Among those who could only breathe with the help of a ventilator, it reduced deaths by 35%.
  • WHO stresses that dexamethasone should only be used for patients with severe or critical illness, under close clinical supervision.

“In patients with progressive deterioration of oxygenation indicators, rapid worsening on imaging and excessive activation of the body's inflammatory response, glucocorticoids can be used for a short period of time (3 to 5 days). It is recommended that the dose should not exceed the equivalent of methylprednisolone 1-2mg/kg/day or dexamethasone 0.2-0.4 mg/kg/day. Note that a larger dose of glucocorticoid will delay the removal of coronavirus due to immunosuppressive effects,”

Health ministry new guidelines says.
  • Dexamethasone medication reduces the number of deaths in those who need oxygen by 20% and by 35% in those who use a ventilator. Also, it is an over-the-counter medication available to everyone.
  • The results of the UK randomized evaluation trial of Covid-19 therapy (RECOVERY) have raised hopes of the ability of existing and reused drugs to mitigate the impact of Covid.
  • India is a bulk manufacturer of dexamethasone. A strip of 20 tablets of 0.5 mg each by Zydus Cadila is available for Rs 6.38. With accessibility and accessibility, dexamethasone could revolutionize Covid's critical care globally and reduce mortality.
  • The RECOVERY trial began in March as a randomized clinical trial to evaluate a variety of potential treatments for Covid-19, including low-dose dexamethasone (a steroid treatment) and more than 11,500 patients from 175 hospitals in the National Health Service from the UK has signed up.
  • A total of 2,104 patients were randomized to receive 6 mg dexamethasone once daily (orally or by intravenous injection) for 10 days and compared with 4,321 patients randomized to receive routine care alone.
  • Dexamethasone reduced deaths by one third in ventilated patients and one fifth in other patients who received only oxygen. Based on these results, treating approximately eight ventilated patients or approximately 25 oxygen-only patients would prevent one death, said study leader Peter Horby.
Delhi University 5 Year Law Programs Registration Begins

Delhi University 5 Year Law Programs Registration Begins

Delhi University has started the registration process for 5 year law programs. Candidates applying for the 5-year law programs can…
Read More
Bar Council of India proposes to hold CLAT and declares NLU Consortium a non-statutory body

Bar Council of India proposes to hold CLAT and declares NLU Consortium a non-statutory body

The Bar Council of India, in a supplementary affidavit filed before the Delhi High Court, proposed to conduct the Common…
Read More
DU UG 2023 Admissions Process Expected to Begin End of May

DU UG 2023 Admissions Process Expected to Begin End of May

Admissions for undergraduate and graduate programs will be by CSAS (UG) 2023 and CSAS (PG) 2023. Delhi University plans to…
Read More
CUET UG 2023 Participating Universities | Central University of Karnataka

CUET UG 2023 Participating Universities | Central University of Karnataka

The Central Karnataka University will start admission for its undergraduate programs from May 21 this year. Admission to these UG…
Read More
AIBE XVII 2023 results published

AIBE XVII 2023 results published

AIBE XVII Result: Candidates who have taken the exam can now check their result on the AIBE website: allindiabarexamination.com. AIVE…
Read More
CUET PG 2023 | Six universities join the CUET PG

CUET PG 2023 | Six universities join the CUET PG

: Interested and eligible candidates can apply until May 5 on the official website: cuet..nic.in. The CUET PG…
Read More
AIBE XVII (17) 2023 result

AIBE XVII (17) 2023 result

Once released, candidates who have taken the AIBE XVII(17) 2023 exam will be able to check their score on the…
Read More
CUET UG 2023 Participating Universities |  Central University of Haryana

CUET UG 2023 Participating Universities |  Central University of Haryana

The university currently has eight schools and 34 departments that offers science and humanities programs. CUET-2023-Preparation CUET UG 2023: The…
Read More
CUET UG 2023 Participating Universities: BHU

CUET UG 2023 Participating Universities: BHU

CUET UG 2023: After Delhi University, received the most applications among central universities. Here is everything you need to…
Read More
CUET PG 2023 to be held June 5-12

CUET PG 2023 to be held June 5-12

CUET PG 2023: Exams will be held daily from June 5-12, i.e. June 5, 6, 7, 8, 9, 10, 11,…
Read More

About Post Author